India’s Cipla Partially Exits Desano Of China; Redeploys Funds Into Biosimilars, APIs
This article was originally published in PharmAsia News
The Indian drug maker has embarked on a new China strategy that includes biosimilars.
You may also be interested in...
TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division
India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push
MUMBAI - Many months after keeping its biosimilars plans under wraps, Cipla - India's second-largest drug maker - shared some parts of its proposed big picture that revolves around a manufacturing site in Goa, India, and another firm in Hong Kong that is putting up a biologics manufacturing facility in Shanghai
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.